Vaccination of BALB/c mice with recombinant truncated fusion protein ED showed high level of protective responses against NTHi.
Nine MAbs were produced after immunizing mice with recombinant hemagglutinin (HA) protein from A/California/06/09.
The group primed mice with recombinant DNA (mSTEAP1 and/or mPSCA) and boosted with modified vaccinia virus ankara (MVA) vector expressing the same antigen(s).
The same effect can be obtained by treating the mice with recombinant anti-MDA-p45 IgG, suggesting that these antibodies have atheroprotective effects.
While these preclinical data demonstrate promise for this strategy an earlier preclinical study by Kim et al. primed mice with recombinant adenoviruses expressing mSTEAP, mPSCA and mPSMA and then boosted with DCs pulsed with tumour lysate [111].
This was in accordance with the findings from previous studies, which indicated that treatment of tumor-bearing mice with recombinant G-CSF could induce the accumulation of MDSCs in vivo (Waight et al., 2011).
Immunization of BALB/c mice with recombinant viruses, demonstrated that serum from the BacSC-σC and BacSC-σB treated models had significant higher levels of virus neutralization activities than the control groups.
Immunisation of the mice with recombinant pGP3 or pGP4 protein caused a significantly lower chlamydial burden in the lungs of the infected mice; the lower IFN-γ level indicated a reduced extent of inflammation.
We found that intratumoral treatments of tumor-bearing mice with recombinant NDV expressing a model TAA elicited an enhanced tumor-specific response, resulting in a significant increase in the number of complete tumor regressions compared with control NDV.
Mucosal immunization of mice with recombinant L. lactis NZ9000 expressing the UreBe-IL-2 conjugated protein elicited more anti-UreB antibodies and more cytokines such as IFN-γ, IL-4 and IL-17, and had a lower H. pylori burden and urease activity than control mice (Zhang et al., 2014).
Accordingly, reconstitution of MBL-null mice with recombinant human MBL (rhMBL) enhanced brain damage.
